发布求助
文献互助 智能选刊 最新文献

Diabetes Spectrum最新文献

筛选
英文 中文
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies 非酒精性脂肪肝的药物治疗方法：当前和未来的疗法
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0012
I. Genua, Kenneth Cusi
{"title":"Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies","authors":"I. Genua, Kenneth Cusi","doi":"10.2337/dsi23-0012","DOIUrl":"https://doi.org/10.2337/dsi23-0012","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"55 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139892751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians 为忙碌的临床医生提供实用的非酒精性脂肪肝生活方式管理方法
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0009
S. Zelber-Sagi, J. Bernadette Moore
{"title":"Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians","authors":"S. Zelber-Sagi, J. Bernadette Moore","doi":"10.2337/dsi23-0009","DOIUrl":"https://doi.org/10.2337/dsi23-0009","url":null,"abstract":"Weight loss achieved through a combination of healthy eating patterns that encompass the principles of the Mediterranean diet and regular physical activity is the most evidence-based treatment for nonalcoholic fatty liver disease. Although other types of diets have demonstrated efficacy in liver fat reduction, the Mediterranean diet confers additional cardiometabolic benefits. Macronutrient composition, food choices, and timing of eating can be tailored to individual preferences, culture, and financial circumstances; however, recommended healthy eating patterns are characterized by minimally processed or unprocessed foods (vegetables, legumes, nuts and seeds, fruits, whole grains, and unprocessed meats and fish) that are low in sugar, refined carbohydrates, and saturated fat and high in fiber, polyphenols, vitamins, minerals, and healthy fats. Physical activity can independently improve steatosis, prevent fibrosis and cirrhosis, and reduce mortality.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"63 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139873923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action 糖尿病患者的非酒精性脂肪肝：行动呼吁
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0015
Kenneth Cusi
{"title":"Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action","authors":"Kenneth Cusi","doi":"10.2337/dsi23-0015","DOIUrl":"https://doi.org/10.2337/dsi23-0015","url":null,"abstract":"","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"144 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139821401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care 胰岛素抵抗在 2 型糖尿病患者非酒精性脂肪肝发展过程中的作用：从工作台到患者护理
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0013
Juan Patricio Nogueira, Kenneth Cusi
{"title":"Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care","authors":"Juan Patricio Nogueira, Kenneth Cusi","doi":"10.2337/dsi23-0013","DOIUrl":"https://doi.org/10.2337/dsi23-0013","url":null,"abstract":"Insulin resistance is implicated in both the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression from steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma, which is known to be more common in people with type 2 diabetes. This article reviews the role of insulin resistance in the metabolic dysfunction observed in obesity, type 2 diabetes, atherogenic dyslipidemia, and hypertension and how it is a driver of the natural history of NAFLD by promoting glucotoxicity and lipotoxicity. The authors also review the genetic and environmental factors that stimulate steatohepatitis and fibrosis progression and their relationship with cardiovascular disease and summarize guidelines supporting the treatment of NAFLD with diabetes medications that reduce insulin resistance, such as pioglitazone or glucagon-like peptide 1 receptor agonists.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"21 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139880606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know 解读《非酒精性脂肪肝临床实践指南》：临床医生须知
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0014
Kenneth Cusi, Jeff Budd, Eric Johnson, Jay H. Shubrook
{"title":"Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know","authors":"Kenneth Cusi, Jeff Budd, Eric Johnson, Jay H. Shubrook","doi":"10.2337/dsi23-0014","DOIUrl":"https://doi.org/10.2337/dsi23-0014","url":null,"abstract":"Standards of care summarized in clinical practice guidelines for nonalcoholic fatty liver disease (NAFLD) offer clinicians a streamlined diagnostic and management approach based on the best available evidence. These recommendations have changed a great deal in recent years; today, there is a clear focus on screening for the early identification and risk stratification of patients at high risk of steatohepatitis and clinically significant fibrosis to promote timely referrals to specialty care when needed. This article reviews and provides the rationale for current guidelines for NAFLD screening, diagnosis, treatment, and monitoring and addresses barriers to providing evidence-based NAFLD care and how to overcome them. The current paradigm of care calls for primary care clinicians and specialists to work together, within a multidisciplinary care team familiar with obesity and diabetes care, to provide comprehensive management of these complex patients.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"11 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139891862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies 非酒精性脂肪肝的药物治疗方法：当前和未来的疗法
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0012
I. Genua, Kenneth Cusi
{"title":"Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies","authors":"I. Genua, Kenneth Cusi","doi":"10.2337/dsi23-0012","DOIUrl":"https://doi.org/10.2337/dsi23-0012","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"219 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139832552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Sincere Thank You to the Reviewers of Diabetes Spectrum 衷心感谢《糖尿病谱》的审稿人
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/ds24-en01
{"title":"A Sincere Thank You to the Reviewers of Diabetes Spectrum","authors":"","doi":"10.2337/ds24-en01","DOIUrl":"https://doi.org/10.2337/ds24-en01","url":null,"abstract":"","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139812426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Sincere Thank You to the Reviewers of Diabetes Spectrum 衷心感谢《糖尿病谱》的审稿人
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/ds24-en01
{"title":"A Sincere Thank You to the Reviewers of Diabetes Spectrum","authors":"","doi":"10.2337/ds24-en01","DOIUrl":"https://doi.org/10.2337/ds24-en01","url":null,"abstract":"","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"55 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139872532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
About Kenneth Cusi: Guest Editor 关于肯尼斯-库西：客座编辑
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/ds24-ge01
{"title":"About Kenneth Cusi: Guest Editor","authors":"","doi":"10.2337/ds24-ge01","DOIUrl":"https://doi.org/10.2337/ds24-ge01","url":null,"abstract":"","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"63 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139813779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action 了解非酒精性脂肪肝的负担：行动起来
Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0010
Z. Younossi, Linda Henry
{"title":"Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action","authors":"Z. Younossi, Linda Henry","doi":"10.2337/dsi23-0010","DOIUrl":"https://doi.org/10.2337/dsi23-0010","url":null,"abstract":"The prevalence of nonalcoholic fatty liver disease (NAFLD) in the United States is 38%, having increased by 50% within the past 3 decades. The estimated NAFLD prevalence among people with type 2 diabetes is 55–70%. The presence of type 2 diabetes is associated with a higher likelihood of progression of NAFLD to fibrosis development, liver transplant, and death. Cardiovascular disease is the main cause of mortality among people with NAFLD, and the risk of death is significantly higher in people with both NAFLD and type 2 diabetes. NAFLD carries high patient and economic burdens but low awareness among both the general public and health care providers. This article reviews the epidemiology of NAFLD and discusses the need for appropriate risk stratification, referral for specialty care, management of cardiometabolic risk factors, and treatment of the disease. The authors present a call to action to raise awareness of NAFLD and address its increasing burden in a systematic and efficient manner.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"30 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139818425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信